within Pharmacolibrary.Drugs.ATC.C;

model C01CX10
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 5.966666666666667e-05,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.226,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010333333333333333,
    Tlag           = 15.0,            
    Vdp             = 0.116,
    k12             = 10.3,
    k21             = 10.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01CX10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Omecamtiv mecarbil is a selective cardiac myosin activator developed for the treatment of heart failure with reduced ejection fraction (HFrEF). It works by increasing cardiac contractility without increasing intracellular calcium concentrations or myocardial oxygen consumption. It has been assessed in clinical trials for chronic heart failure, but is not widely approved for routine use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Liu, LC, et al., &amp; Voors, AA (2016). Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. <i>Expert opinion on investigational drugs</i> 25(1) 117–127. DOI:<a href=\"https://doi.org/10.1517/13543784.2016.1123248\">10.1517/13543784.2016.1123248</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26587768/\">https://pubmed.ncbi.nlm.nih.gov/26587768</a></p></li><li><p>Trivedi, A, et al., &amp; Lee, E (2021). Pharmacokinetics, Disposition, and Biotransformation of [. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 49(8) 619–628. DOI:<a href=\"https://doi.org/10.1124/dmd.121.000444\">10.1124/dmd.121.000444</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34011533/\">https://pubmed.ncbi.nlm.nih.gov/34011533</a></p></li><li><p>Trivedi, A, et al., &amp; Lee, E (2021). Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil. <i>Clinical pharmacokinetics</i> 60(8) 1041–1048. DOI:<a href=\"https://doi.org/10.1007/s40262-021-01014-0\">10.1007/s40262-021-01014-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33768487/\">https://pubmed.ncbi.nlm.nih.gov/33768487</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01CX10;
